Last updated on April 24, 2014 at 5:50 EDT

Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins

April 3, 2013

JERUSALEM, April 3, 2013 /PRNewswire/ –

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of
oral drug delivery systems, announced today that it has received approval for a key patent
by the Japanese Patent Office. The patent, titled “Methods and Compositions for Oral
Administrations of Proteins,” covers a core concept of the company’s technology. The
patent has also been approved in Israel and Australia. Oramed’s portfolio now consists of
seven issued patents and 28 patents pending.

According to a report [http://www.efpia.eu/sites/www.efpia.eu/files/EFPIA Figures 2012
Final.pdf ] by the European Federation of Pharmaceutical Industries and Associations,
Japan constitutes 12% of the global sales of new medicines launched in the period from
2006 to 2010.

Nadav Kidron, CEO of Oramed, commented, “We are very excited to add the Japanese
patent to our international portfolio. The Japanese patent approval represents a great
success in further establishing the global standing of Oramed’s innovative oral delivery

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s
technology is based on over 30 years of research by top research scientists at Jerusalem’s
Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes
through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801)
currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide
capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company’s
corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please
visit http://www.oramed.com

The company’s fact sheet can be viewed here
[http://oramed.com/ufiles/Oramed%20%20fact%20sheet%20March2013-website.pdf ].

Safe Harbor for Forward-Looking Statements: This press release contains
forward-looking statements. For example, we are using forward-looking statements when we
discuss our approaching of phase 2 clinical trials. These forward-looking statements are
based on the current expectations of the management of Oramed only, and are subject to a
number of factors and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical trials and
product development programs; difficulties or delays in obtaining regulatory approval or
patent protection for our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional funding required to conduct
our research, development and commercialization activities. In addition, the following
factors, among others, could cause actual results to differ materially from those
described in the forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new technologies, products and
applications; lack of validation of our technology as we progress further and lack of
acceptance of our methods by the scientific community; inability to retain or attract key
employees whose knowledge is essential to the development of our products; unforeseen
scientific difficulties that may develop with our process; greater cost of final product
than anticipated; loss of market share and pressure on pricing resulting from competition;
laboratory results that do not translate to equally good results in real settings; our
patents may not be sufficient; and final that products may harm recipients, all of which
could cause the actual results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required by law,
Oramed undertakes no obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to
time with the Securities and Exchange Commission.

        Company and Investor Relations Contact:
        Aviva Sherman
        USA:   +1-646-240-4193
        Int'l: +972-2-566-0001
        E-mail: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.

Source: PR Newswire